The Department of Health and Human Services has awarded Profectus BioSciences an $8.6 million contract to further develop and test a vaccine designed to treat infections caused by Ebola and Marburg viruses.
HHS said Tuesday the cost-plus-fixed-fee contract covers research and development of Profectus’ Ebola and Marburg filovirus vaccine rVSVN4CT1.
Profectus presented data from animal studies on the injectable drug at the Filovirus Medical Countermeasures Meeting hosted by the National Institutes of Health in Maryland last year.
The biotechnology firm said its rVSV‐based vaccines gave 100 percent protection to monkeys from Ebola and Marburg during government-backed research.
According to the company, the rVSV vaccine delivery vector is designed to trigger antibody responses in the surface glycoproteins of several infectious diseases as well as biothreat agents.